The development of an oral antidiabetic combination tablet: Design, evaluation and clinical benefits for patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 19, Issue 3, 2003, Pages 218-225

  Howlett, H ^a   Porte, F ^a   Allavoine, T ^a   Kuhn, T ^a   Nicholson, G ^a  

^a Merck Santé ^*  (United Kingdom)

Author keywords

Combination therapy; Glibenclamide; Glyburide; Metformin; Oral antidiabetic agent; Pharmacokinetics; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE PLUS METFORMIN; GLIPIZIDE PLUS METFORMIN; METFORMIN PLUS ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; TABLET;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; TABLETS;

EID: 0038583502     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001730     Document Type: Article

References (28)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
2. New JP, Hollis S, Campbell F, et al. Measuring clinical performance and outcomes from diabetes information systems: an observational study. Diabetologia 2000;43:836-43
3. Reasner CA, Göke B. Overcoming the barriers to effective glycaemic control for type 2 diabetes. Br J Diabetes Vas Dis 2002;2:290-5
4. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
6. Waeber B. Fixed low-dose combination therapy for hypertension. Curr Hypertens Rep 2002;4:298-306
7. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9
8. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994;11:953-60
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
10. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89-130
11. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
13. Scheen AJ, Jaminet C, Luyckx AS, Lefebvre PJ. Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. Int J Clin Pharmacol Ther Toxicol 1987;25:70-6
14. Carlson RF, Isley WL, Ogrinc FG, Klobucar TR. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther 1993;15:788-96
15. Marathe PH, Arnold ME, Meeker J, et al. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol 2000;40:1494-1502
16. EMEA Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. London: EMEA, 2001
17. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance®) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002;41:1301-9
18. Blonde L, Rosenstock J, Mooradian AD, et al. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002;4:368-75
19. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201-8
20. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84
21. Morris AD, Brennan GM, Macdonald TM, Donnan PT. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000;49(Suppl 1):A76
22. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001;23:1311-20
23. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30:71-9
24. Melikian C, White TJ, Vanderplas A, Derji CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organisation: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther 2002;24:460-7
25. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
26. Abbasi F, Kamath V, Rizvi AA, Carantoni M, Chen YD, Reaven GM. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care 1997;20:1863-9
27. Rubin CJ, Soufer J, Pieters A, Fiedorek FT Glipizide/metformin tablets as first-line treatment in type 2 diabetes: efficacy, safety, and tolerability. Diabetes 2002;51 (Suppl 2):A113
28. Rubin CJ, Meneghini L, Pans M, Fiedorek FT. Glipizide/metformin tablets as second-line therapy in type 2 diabetes: efficacy, safety, and tolerability. Diabetes 2002;51 (Suppl 2):A113